Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

Stopped early

Conditions studied: Carcinoma, Renal Cell

In brief

The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment

Key facts

Study ID

NCT05534789

Run by

Pfizer

People needed

106

Starts

2022-10-15

Expected to finish

2023-12-13

Last updated by the study team

2025-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants diagnosed with locally advanced or metastatic renal cell carcinoma
• Participants with full medical information is available regarding all treatments before, during and after 1st line

Where it is running

• Pfizer New York — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.